We describe a simple, sensitive assay for oxalate in urine or plasma. Acidified urine is pretreated by dilution with neutral phosphate buffer and passage through a C,8 cartridge. Stabilized plasma is diluted with neutral acetate buffer and oxalate extracted using a strong anion exchange cartridge. Treated samples are applied to an ion-paired chromatographic system and oxalate detected electrochemically. Recovery of oxalate from augmented samples exceeded 97% from both urine and plasma. Within-and between-assay coefficients of variation assessed at three concentrations were, respectively, better than 4.1% and 8.4% for urine and 3.9% and 5.2% for plasma. The reference range for urinary oxalate excretion is 109-497 pmo1/24 h. The range for plasma oxalate concentration is 0.6-2.8 pmol/L or 0.7-3.9 pmol/L after an overnight fast or without dietary restriction, respectively. Urine and plasma oxalate concentrations from this method, gave correlation
coefficients (r) of 0.97 and 0.98, respectively, when compared with those from established oxalate oxidase based assays.
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Measurement of oxalate concentration in blood and urine is important in the investigation of urolithiasis, chronic renal failure, primary hyperoxaluria and intestinal malab~orption.'-~ Many methods for the determination of oxalate in plasma or urine have been reported. Earlier methods,* involving precipitation, solvent extraction, isotope dilution or enzymic reactions were often laborious, insensitive, expensive and inaccurate. Subsequent methodP8 including gas and liquid chromatographic procedures and improved enzymic techniques, have greater precision and accuracy, but are often c~m p l e x ,~ require large sample v o l~m e s ,~ are prone to interferencelo or cannot be applied to both plasma and urine."
High performance liquid chromatography (HPLC) offers specificity and sensitivity. Published HPLC methods for oxalate have, to date, been largely limited to urine and have required extensive sample preparation and derivati~ation~.'~ or Correspondence: Mr I D K Fry. specialized ion chromatographic equipment. 13.14 The method presented here combines the specificity of HPLC with the sensitivity of electrochemical detection and requires minimal sample preparation and no derivatization. It is applicable to both urine and plasma samples, and is therefore ideal for use in metabolic studies. 
MATERIALS AND METHODS

Equipment and reagents
581
Reagents (analytical grade) were obtained from BDH Ltd (Poole, UK) with the exception of hexadecyltrimethylammonium bromide (cetrimide) from Fisons Ltd (Loughborough, UK); HPLC grade methanol (Rathburn Chemicals Ltd, Peebleshire, UK); dl-dithiothreitol and oxalic acid dihydrate (Sigma Chemical Co., Poole, UK) and helium (BOC, Crawley, UK). Commercial kits for comparative determination of oxalate in urine were a gift from Sigma Chemical Co. (product number 591). Results for plasma oxalate were compared with those from a previously published enzymic method. 2 The HPLC mobile phase comprising 100 mmol/L phosphate buffer, pH 7-0: methanol (90: 10 v/v) was helium-degassed prior to use. The column conditioning solution consisted of methanol: water (25:75 v/v) containing 2 mmol/L cetrimide.
Aqueous standards typically in the concentration range 0-40pmoVL for plasma oxalate and 0-600 pmol/L for urinary oxalate analysis were prepared from stock (10 mmol/L) oxalic acid solution immediately prior to use. Stock oxalic acid solution was stored at 4°C and prepared at 3-monthly intervals.
Preliminary studies
Optimum conditions for sample pretreatment were developed by assessing recovery of added oxalate from plasma and urine samples subjected to different extraction procedures. Extraction of oxalate from plasma using SAX cartridges was optimized with respect to the pH, volume and molarity of diluent buffer, wash solution composition, and eluent buffer pH and ionic strength. Conditions were chosen to give maximum recovery and optimum resolution of oxalate on the chromatographic system. The effects of different pH and different initial dilution upon the Bond ElutTM C,, pretreatment of urine samples were also assessed and conditions optimized for maximum recovery.
Chromatographic conditions were chosen to give the shortest retention time compatible with complete resolution of oxalate from other extracted moieties. Possible interference from other compounds was investigated by addition of these substances to urine and plasma at concentrations of twice that expected to occur either physiologically or pathologically.
Final procedure
Sample collection: Heparinized blood samples were centrifuged within 30 min of collection.
Plasma (1 mL) was stabilized by addition of 20 pL dl-dithiothreitol(12-5 mmol/L), stored at -70°C and analysed within 4 weeks. Twenty-four hour urine specimens were collected into bottles containing 20 mL 6M-HCI as preservative and the pH checked on receipt at the laboratory to ensure that it was below pH 1.5.
Plasma extraction
Two millilitres acetate buffer (50 mmol/L, pH 7 -0) was added to 1 mL stabilized plasma or standard. The solution was mixed and passed through a Bond ElutTM SAX column preconditioned with 1 mL methanol and 1 mL acetate buffer (50 mmol/L, pH 7-0). The column was then washed with 2 mL acetate buffer (50 mmol/L, pH 7.0) and oxalic acid was eluted with two 400 pL aliquots of 600 mmol/L potassium dihydrogen orthophosphate, pH 3 .O (adjusted with 600 mmol/L orthophosphoric acid). Eluates were mixed and 1OOpL taken for chromatography.
Urine extraction
Eight hundred microlitres phosphate buffer (100mmol/L, pH 7.0) was added to 200pL acidified urine. The solution was passed through a Bond ElutTM C I 8 column preconditioned with 1 mL methanol and 1 mL phosphate buffer (100mmol/L, pH7.0). A sample (20pL) of eluate was taken for chromatography.
Chromatography
The analytical column was preconditioned by pumping to waste, at 1 mL per min, 200mL cetrimide preconditioning solution followed by 200mL mobile phase. After connecting the electrochemical detector, the mobile phase was recirculated and replaced every 2-4 weeks depending upon workload. The ion-pair system generated gave reproducible retention times for 2-6 months (approximately 800 injections) after which shortened retention time or unacceptable peak broadening necessitated column reconditioning or replacement. Samples were assayed at ambient temperature using a flow rate of 1.2 mL/ min, 1250 mV applied potential, DC mode and a time constant of 5 s. The sensitivity setting required depended upon the condition of the electrode but was typically 1 .O pA full scale for urine and 0.5 pA full scale for plasma analysis. precision data are summarized in Table 1 . Recovery studies, assessed by analysis of urine and plasma samples before and after addition of known amounts of oxalate, gave the results in Table 2 . The limit of linearity was shown to exceed lo00 pmol/L for urinary oxalate analysis and 50 pmol/L for plasma oxalate analysis. The limit of detection, defined as the lowest oxalate concentration distinguishable from baseline noise with 95% confidence, was 35 pmol/L for urine and 0.5pmol/L for plasma oxalate using the analytical conditions described. Investigation of optimum urine dilution showed that even the most concentrated urine gave maximum oxalate recovery provided a fivefold dilution was used. Dilution in phosphate buffer at a molarity of 100 mmol/L and pH 7.0 resulted in a final pH above pH 6 -2 (i.e., two pH units above the highest pK, of oxalic acid) ensuring almost complete ionization of oxalate and its nonretention on the C,, preparative column. Studies of sample stability demonstrated that urine samples collected as described had p H values less than pH 1 -5 and were stable with respect to oxalate concentration for at least 4 months at -20°C. The pH of urine diluted for analysis was in this range of pH 6-2-pH 6.6. We demonstrated that no detectable oxalogenesis occurred in urine samples augmented with up to 20 mmol/L ascorbic acid, provided the assay was completed within 4 h of urine dilution. Likewise, addition of dl-dithiothreitol to plasma prevented conversion of ascorbic acid to oxalic acid up to a plasma ascorbate concentration exceeding 400 pmol/L. Plasma samples prepared as described were stable with respect to oxalate concentration for at least 7 days at -20°C or 4 weeks at -70°C.
RESULTS
Interference studies ( Table 3) showed that there was no analytical interference from any of the compounds tested. These substances were added to urine and plasma at concentrations in at least a twofold excess of those expected to occur and samples were subjected to the complete analytical procedure. Of the substances tested only pyruvic acid had a retention time similar to that of oxalic acid and even this showed baseline resolution. lncubation of urine and plasma samples with oxalate oxidase (EC 1.2.3.4.) resulted in the complete loss of the oxalate peak on chromatography. This indicated that the chromatographic peak identified from standard material as oxalic acid contained no other co-chromatographing component.
Correlation data are shown in Fig. 2 . Comparison of the method presented with a commercial kit using oxalate oxidase for urine oxalate Reference ranges for oxalate in urine and plasma determined in healthy subjects (age range; 20-56 years) on an unrestricted diet are shown in Table 4 . The range of oxalate concentration in plasma samples collected after an overnight (12 h) fast is also shown.
DISCUSSION
The method described facilitates analysis of oxalate both in plasma and in urine by the same chromatographic system. The system is similar to that previously de~cribed,'~ but has been adapted for use with the more conventional glassy carbon Co., producl no. 591) . recently reported ion chromatographic method14 only a short equilibration time is necessary, sample throughput is relatively rapid and dedicated instrumentation is not required. Sample pretreatment differs for plasma and urine specimens. Dilution of stabilized acidified urine with neutral phosphate buffer results in a pH of 6 -2 to pH 6.6. Oxalogenesis from ascorbic acid occurs in this pH range (unpublished results) but investigation showed that samples were stable with respect to oxalate concentration even in urine augmented with 20 mmol/L ascorbic acid, provided the assay was completed within 4 h of sample dilution. Plasma samples were shown to be stable with respect to oxalogenesis from ascorbate provided the strong reducing agent dldithiothreitol was added at the time of collection. Close attention to detail in sample collection and storage to avoid spurious elevation of oxalate concentration is vital, and poorly designed sample collection protocols may contribute to the large variation in reference range reported for plasma' and urine8 oxalate concentration.
b) urine method versus enzymic urine oxalate kit (Sigma Chemical
Correlation of results from HPLC oxalate method: (a) plasma method versus enzymic plasma oxalate
A recent report' has suggested that oxalate in plasma may be protein-bound at low pH. Dilution of plasma in acetate buffer at neutral pH not only ensures that oxalate is ionized and therefore binds to the anion exchanger, but also prevents any potential losses by protein binding. The method described therefore results in quantitative recovery of oxalate from plasma ( Table 2 ). Thus preliminary ultrafiltration of plasma samples to prevent oxalate loss through protein binding, as suggested by some authors" is unnecessary. The use of the anion exchange procedure produced a very clean extract for chromatography. Since no suitable internal standard could be identified for the assay reproducible extraction efficiency, as demonstrated in the method described, is essential.
Pretreatment of urine samples with C,, cartridges has been used by other authors under a variety of condition^.'^^'^ Using the method described these cartridges could be re-used several times provided they are pretreated with methanol and phosphate buffer and close attention is paid to oxalate recovery. The pretreatment procedure for urine is unsuitable for plasma analysis since the clean-up achieved is insufficient and the dilution required results in unacceptably low sensitivity at the much lower oxalate concentrations found in plasma.
In agreement with a previous reportI3 we found no sex-related differences in the reference ranges for urinary oxalate output. The reference range found for urinary oxalate excretion is in agreement with other reports13 using physical methods but is lower than that reported for an enzymic procedure," possibly reflecting the higher selectivity of the method currently described ( Table 5 ) . The range found for urinary oxalate output showed a normal distribution with an upper limit approximating t o 500 pmo1/24 h. In our view, however, patients in whom oxalate output exceeds 450 pmo1/24 h warrant further investigation in view of the importance of oxalate as a risk factor in renal stone formation.
The range for plasma oxalate concentration ( Table 5 ) agrees with that from in-vivo isotope dilution s t~d i e s l~*~ and recent enzymic methods2V2O indicating that the method is substantially interference free, as confirmed by the interference studies performed ( Table 3 ). The effect of diet shown in our study may be a contributory factor in some of the higher reference ranges previously reported for non-fasting subjects.' Diet has been shown previously26 to affect urinary oxalate output and would therefore be expected to affect plasma oxalate concentration. Dietary intake of oxalate or its precursors must therefore be considered when interpreting results. Another factor which may contribute to differences between reference ranges reported for both urine and plasma is oxalogenesis from ascorbic acid or other precursors during sample collection, storage or analysis.
Comparative studies (Fig. 2 ) demonstrated excellent agreement between plasma oxalate results from this method and those from a previously reported procedure.2 This correlation In vivo Isotope dilution 24 Oxalate oxidase 21 Immobilized oxalate 23 Ion chromatography 14 Oxalate decarboxylase 48 HPLC 32 oxidase *Fasting range. NG, Not given.
probably results in part from the fact that the samples for comparison were collected simultaneously and stored identically prior to analysis thereby reducing pre-analytical variables to a minimum. Comparison of urine oxalate values with those from the commercially available kit also showed acceptable correlation suggesting that the modifications made by the manufacturer to minimize the reported ascorbate interferencelo in this methodology have been successful.
In summary, the method described is simple enough for routine use and possesses the sensitivity and selectivity of HPLC with electrochemical detection. A strict sample collection and storage procedure prevents oxalogenesis, and oxalate losses during sample pretreatment are minimal. The accuracy and precision of the method, coupled to the fact that it is applicable to both plasma and urine, make it ideal for use in metabolic studies.
